MYC and acute myeloid leukemia: CDK9 inhibitors demonstrate efficacy in downregulating MYC transcripts and Myc stability across hepatocellular carcinoma [53], mixed-lineage leukemia [85], diffuse large B-cell lymphoma [86], acute myeloid leukemia [87], and pancreatic cancer [88].